The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma.

ABSTRACT: As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge especially because of a marked heterogeneity in the population and an increased susceptibility to treatment toxicity. Indeed, the balance between efficacy and safety must be considered at all time throughout the treatment history for these patients. Therefore, younger and older patients were historically treated in a very different way, even though the safety profile of most anti-myeloma drugs has drastically improved over the years. The emergence of immunotherapy (IT) has largely widened the therapeutic options available in MM and above all has allowed

SUBMITTER: Bobin A 

PROVIDER: S-EPMC7218111 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature